Skip to content
10-K

Annual Report

Metagenomi Therapeutics, Inc. MGX

0000950170-25-040217

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 37.38M sh
Shares Diluted FY 2024 · Dec 31, 2023 3.4M sh
Capex FY 2024 · Dec 31, 2023 $9.81M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$91.41M
Cash And Equivalents FY 2024 · Dec 31, 2023 $140.6M
Current Liabilities FY 2024 · Dec 31, 2023 $68.86M
Total Liabilities FY 2024 · Dec 31, 2023 $149.67M
Current Assets FY 2024 · Dec 31, 2023 $278.27M
Total Assets FY 2024 · Dec 31, 2023 $364.84M
Eps Diluted FY 2024 · Dec 31, 2023 −$20.05
Eps Basic FY 2024 · Dec 31, 2023 −$20.05
Sga Expense FY 2024 · Dec 31, 2023 $28.85M
Rd Expense FY 2024 · Dec 31, 2023 $94.4M
Net Income FY 2024 · Dec 31, 2023 −$68.26M
Operating Income FY 2024 · Dec 31, 2023 −$78.49M
Revenue FY 2024 · Dec 31, 2023 $44.76M
Stockholders Equity FY 2024 · Dec 31, 2022 −$74.43M